People with diabetes have an increased risk of developing serious health problems, including neuropathy. We’ve developed an AI-based system, in partnership with eminent specialists, to assess the presence of neuropathy from retinal images.
Author profile
Matthew Allen
Head of Pharma
After several years leading our drug delivery device market development, Matthew now oversees global business development for our medical technology business, including drug delivery, medical devices, diagnostics and digital health.
His role involves strategic responsibility of business development as well as technical and commercial oversight of some of our most complex development projects, with a specific interest in inhalation and injection products.
My insights
Miniature active implants for next-generation drug delivery
Advances in drug delivery medical devices has remained constant for 30 years. But now, we are entering an exciting new era of innovation with a new generation of miniature active implantable medical devices (AIMDs) for drug delivery.